{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,20]],"date-time":"2025-11-20T18:56:48Z","timestamp":1763665008525,"version":"3.41.0"},"reference-count":22,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"11","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,11]]},"abstract":"<jats:title>Abstract:<\/jats:title>\n          <jats:p>Although pneumococcal vaccination programs have significantly reduced the incidence of pneumococcal infections in the US, pneumococcal pneumonia continues to be a burdensome cause of morbidity and mortality. Pneumococcal vaccination recommendation updates were recently published and introduce two new pneumococcal conjugate vaccines for use in adults ages 19 and older.<\/jats:p>","DOI":"10.1097\/01.npr.0000897220.84850.82","type":"journal-article","created":{"date-parts":[[2022,10,26]],"date-time":"2022-10-26T16:19:25Z","timestamp":1666801165000},"page":"40-47","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["Pneumococcal vaccination for adults"],"prefix":"10.1097","volume":"47","author":[{"given":"Jana L.","family":"Esden","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"issue":"4","key":"R5-20250607","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1080\/21645515.2018.1564434","article-title":"Disparities in uptake of 13-valent pneumococcal conjugate vaccine among older adults in the United States","volume":"15","author":"McLaughlin","year":"2019","journal-title":"Hum Vaccin Immunother"},{"issue":"14","key":"R6-20250607","doi-asserted-by":"crossref","first-page":"1951","DOI":"10.1016\/j.vaccine.2021.02.061","article-title":"Role of social determinants of health in pneumococcal vaccination among high-risk adults","volume":"39","author":"Gatwood","year":"2021","journal-title":"Vaccine"},{"author":"Gierke","key":"R8-20250607","article-title":"Pneumococcal disease"},{"issue":"6 suppl 4","key":"R11-20250607","doi-asserted-by":"crossref","first-page":"S383","DOI":"10.1016\/j.amepre.2015.09.008","article-title":"Pneumococcal disease prevention among adults: strategies for the use of pneumococcal vaccines","volume":"49","author":"Pilishvili","year":"2015","journal-title":"Am J Prev Med"},{"issue":"37","key":"R16-20250607","first-page":"822","article-title":"Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine among adults aged \u226565 years: recommendations of the Advisory Committee on Immunization Practices (ACIP)","volume":"63","author":"Tomczyk","year":"2014","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"34","key":"R17-20250607","doi-asserted-by":"crossref","first-page":"944","DOI":"10.15585\/mmwr.mm6434a4","article-title":"Intervals between PCV13 and PPSV23 vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP)","volume":"64","author":"Kobayashi","year":"2015","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"46","key":"R18-20250607","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.15585\/mmwr.mm6846a5","article-title":"Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine among adults aged \u226565 years","volume":"68","author":"Matanock","year":"2019","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"4","key":"R19-20250607","doi-asserted-by":"crossref","first-page":"109","DOI":"10.15585\/mmwr.mm7104a1","article-title":"Use of 15-valent pneumococcal conjugate vaccine and 20-valent pneumococcal conjugate vaccine among U.S. adults: updated recommendations of the Advisory Committee on Immunization Practices \u2013 United States, 2022","volume":"71","author":"Kobayashi","year":"2022","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"37","key":"R21-20250607","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.15585\/mmwr.mm7137a3","article-title":"Use of 15-Valent Pneumococcal Conjugate Vaccine Among U.S. Children: Updated Recommendations of the Advisory Committee on Immunization Practices - United States, 2022","volume":"71","author":"Kobayashi","year":"2022","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"1","key":"R22-20250607","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1093\/cid\/ciy872","article-title":"Impact of the 13-valent pneumococcal conjugate vaccine among adults: a systematic review and meta-analysis","volume":"69","author":"Vadlamudi","year":"2019","journal-title":"Clin Infect Dis"},{"issue":"suppl 5","key":"R23-20250607","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1111\/j.1469-0691.2012.03937.x","article-title":"Understanding the burden of pneumococcal disease in adults","volume":"18","author":"Blasi","year":"2012","journal-title":"Clin Microbiol Infect"},{"issue":"3","key":"R24-20250607","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1038\/nri2494","article-title":"Maintaining protection against invasive bacteria with protein-polysaccharide conjugate vaccines","volume":"9","author":"Pollard","year":"2009","journal-title":"Nat Rev Immunol"},{"issue":"9","key":"R25-20250607","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1093\/infdis\/jis212","article-title":"Pneumococcal conjugate and plain polysaccharide vaccines have divergent effects on antigen-specific B cells","volume":"205","author":"Clutterbuck","year":"2012","journal-title":"J Infect Dis"},{"issue":"31","key":"R26-20250607","doi-asserted-by":"crossref","first-page":"4701","DOI":"10.1016\/j.vaccine.2018.06.018","article-title":"Serotype distribution of invasive Streptococcus pneumoniae in adults 65 years of age and over after the introduction of childhood 13-valent pneumococcal conjugate vaccination programs in Canada, 2010-2016","volume":"36","author":"Demczuk","year":"2018","journal-title":"Vaccine"},{"issue":"11","key":"R27-20250607","doi-asserted-by":"crossref","first-page":"1780","DOI":"10.1093\/cid\/cix685","article-title":"Comparison of the impact of pneumococcal conjugate vaccine 10 or pneumococcal conjugate vaccine 13 on invasive pneumococcal disease in equivalent populations","volume":"65","author":"Naucler","year":"2017","journal-title":"Clin Infect Dis"},{"issue":"3","key":"R28-20250607","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1093\/cid\/ciab990","article-title":"Pivotal phase 3 randomized clinical trial of the safety, tolerability, and immunogenicity of 20-valent pneumococcal conjugate vaccine in adults aged \u226518 years","volume":"75","author":"Essink","year":"2022","journal-title":"Clin Infect Dis"},{"issue":"38","key":"R29-20250607","doi-asserted-by":"crossref","first-page":"5428","DOI":"10.1016\/j.vaccine.2021.07.004","article-title":"A phase 3, randomized, double-blind study to evaluate the immunogenicity and safety of 3 lots of 20-valent pneumococcal conjugate vaccine in pneumococcal vaccine-na\u00efve adults 18 through 49 years of age","volume":"39","author":"Klein","year":"2021","journal-title":"Vaccine"},{"issue":"51","key":"R30-20250607","doi-asserted-by":"crossref","first-page":"7494","DOI":"10.1016\/j.vaccine.2021.10.032","article-title":"A trial to evaluate the safety and immunogenicity of a 20-valent pneumococcal conjugate vaccine in populations of adults \u226565 years of age with different prior pneumococcal vaccination","volume":"39","author":"Cannon","year":"2021","journal-title":"Vaccine"},{"issue":"3","key":"R31-20250607","doi-asserted-by":"crossref","first-page":"ofab605","DOI":"10.1093\/ofid\/ofab605","article-title":"Immunogenicity, safety, and tolerability of V114, a 15-valent pneumococcal conjugate vaccine, in immunocompetent adults aged 18\u201349 years with or without risk factors for pneumococcal disease: a randomized phase 3 trial (PNEU-DAY)","volume":"9","author":"Hammitt","year":"2021","journal-title":"Open Forum Infect Dis"},{"issue":"1","key":"R32-20250607","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.vaccine.2021.08.049","article-title":"A phase 3 trial of safety, tolerability, and immunogenicity of V114, 15-valent pneumococcal conjugate vaccine, compared with 13-valent pneumococcal conjugate vaccine in adults 50 years of age and older (PNEU-AGE)","volume":"40","author":"Platt","year":"2022","journal-title":"Vaccine"},{"issue":"9","key":"R33-20250607","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1016\/j.vaccine.2021.12.067","article-title":"Lot-to-lot consistency, safety, tolerability, and immunogenicity of V114, a 15-valent pneumococcal conjugate vaccine, in healthy adults aged \u226550 years: a randomized phase 3 trial (PNEU-TRUE)","volume":"40","author":"Simon","year":"2022","journal-title":"Vaccine"},{"issue":"7","key":"R37-20250607","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1093\/infdis\/jiaa515","article-title":"Marked reduction of socioeconomic and racial disparities in invasive pneumococcal disease associated with conjugate pneumococcal vaccines","volume":"223","author":"Raman","year":"2021","journal-title":"J Infect Dis"}],"container-title":["The Nurse Practitioner"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/01.NPR.0000897220.84850.82","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,7]],"date-time":"2025-06-07T17:00:18Z","timestamp":1749315618000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/01.NPR.0000897220.84850.82"}},"subtitle":["History and updates"],"short-title":[],"issued":{"date-parts":[[2022,11]]},"references-count":22,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.1097\/01.npr.0000897220.84850.82","relation":{},"ISSN":["0361-1817"],"issn-type":[{"type":"print","value":"0361-1817"}],"subject":[],"published":{"date-parts":[[2022,11]]}}}